Using PCGEM1 to detect, treat, and prevent prostate cancer. 2004, 12:7. U.S. Patent 6,828,4292[P]. Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y, Padhye S, Sarkar FH: Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 2012, 72:335?45. Lim L, Balakrishnan A, Huskey N, Jones KD, Jodari M, Ng R, Song G, Riordan J, Anderton B, Cheung ST, Willenbring H, Dupuy A, Chen X, Brown D, Chang AN, Goga A: MicroRNA-494 within an oncogenic microRNA megaclusterHe et al. Journal of Experimental Clinical Cancer Research 2014, 33:72 http://www.jeccr.com/content/33/1/Page 10 of28.29.30.31.32.33.34.35.36. 37. 38.39.40.41.42.43.44.45.46.regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology 2014, 59:202?15. Hart M, Wach S, Nolte E, Szczyrba J, Menon R, Taubert H, Hartmann A, Stoehr R, Wieland W, Gr ser FA, Wullich B: The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer. FEBS J 2013, 280:2105?116. Jongen-Lavrencic M, Manova-Todorova K, Teruya-Feldstein J, Avigan DE, Delwel R, Pandolfi PP: The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 2013, 13:87?01. Yamasaki T, Yoshino H, Enokida H, Hidaka H, Chiyomaru T, Nohata N, Kinoshita T, Fuse M, Seki N, Nakagawa M: Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. Int J Oncol 2012, 40:1821?830. Song SJ, Ito K, Ala U, Kats L, Webster K, Sun SM, Jongen-Lavrencic M, Manova-Todorova K, Teruya-Feldstein J, Avigan DE, Delwel R, Pandolfi PP: The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 2013, 13:87?01. Ozen M, Creighton CJ, Ozdemir M, Ittmann M: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008, 27:1788?793. Chen X, Gong J, Zeng H, PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/27735993 Chen N, Huang R, Huang Y, Nie L, Xu M, Xia J, Zhao F, Meng W, Zhou Q: MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res 2010, 70:2728?738. He JH, Li YG, Hang ZP, Wang L, Chun SY, He ML: Analysis biological information for PCGEM1 and speculate the molecular control network express in the prostate cancer. Chin Med Biotechnol 2013, 5:388?91. He JH, Li YG, Chen SY, Wang L: Construction of the eukaryotic expression vector targeting hsa-miR-203 and its effects on proliferation and apoptosis of K562 cell lines. Chin J Clin Lab Sci 2012, 30:595?98. Ponting CP, Oliver PL, Reik W: Evolution and functions of long noncoding RNAs. Cell 2009, 136:629?41. Wilusz JE, Sunwoo H, Spector DL: Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 2009, 23:1494?504. Liu D, Xu B, Chen S, Yang Y, Zhang X, Liu J, Lu K, Zhang L, Liu C, Zhao Y, Jiang H, Liu N, Chen M: Long Non-Coding RNAs and Prostate Cancer. J Nanosci AZD3759 mechanism of action Nanotechnol 2013, 13:3186?194. Ifere GO, Ananaba GA: Prostate cancer gene expression marker 1 (PCGEM1): a patented prostate-specific non-coding gene and regulator of prostate cancer progression. Recent Pat DNA Gene Seq 2009, 3:151?63. Kogure T, Yan IK, Lin WL, Patel T: Extracellular Vesicle-Mediated Transfer of a Novel Long Noncoding RNA TUC339: A Mechanism of Intercellular Signaling in Human Hepatocellular Cancer. Genes Cancer 2013, 4:261?72. Panzitt K, Tschernatsch MM, Guelly C, Moust.